Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

Exclusion Criteria

• •sIgM+;
• •ALL evolved from chronic myeloid leukemia (CML);
• •Down's syndrome, or major congenital or hereditary disease with organ dysfunction;
• •Other secondary leukemias;
• •CNS involvement;
• •History of epilepsy; or convulsions within the last month;
• •Known underlying congenital immunodeficiency or metabolic disease;
• •Congenital heart disease with cardiac insufficiency;
• •Treated with glucocorticoids for ≥14 days, or ABL kinase inhibitors for \> 7 days within one month before enrollment, or any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression);
• •Initial diagnosis of high risk;
• •D46MRD ≥1%.